GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SeqLL Inc (OTCPK:SEQL) » Definitions » 3-Year FCF Growth Rate

SeqLL (SEQL) 3-Year FCF Growth Rate : -73.50% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is SeqLL 3-Year FCF Growth Rate?

SeqLL's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-2.68.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -73.50% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -24.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 7 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of SeqLL was 12.60% per year. The lowest was -73.50% per year. And the median was -24.75% per year.


Competitive Comparison of SeqLL's 3-Year FCF Growth Rate

For the Diagnostics & Research subindustry, SeqLL's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SeqLL's 3-Year FCF Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, SeqLL's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where SeqLL's 3-Year FCF Growth Rate falls into.



SeqLL 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


SeqLL  (OTCPK:SEQL) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


SeqLL 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of SeqLL's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


SeqLL (SEQL) Business Description

Traded in Other Exchanges
N/A
Address
3 Federal Street, Billerica, MA, USA, 01821
SeqLL Inc is an early commercial-stage life sciences instrumentation and research services company engaged in the development of scientific assets and novel intellectual property across multiple omics fields. The company leverages its expertise with True Single Molecule Sequencing (tSMS) technology enabling researchers and clinicians to contribute advancements to scientific research and development by accelerating one's understanding of the molecular mechanisms of disease and fundamental biological processes, It enables researchers to identify and synthesize DNA or RNA strands, irrespective of abundance, in a biological sample and is capable of analyzing billions of molecules in parallel.
Executives
Douglas Patrick Miscoll director 317 NEW BOSTON STREET, SUITE 2010, WOBURN MA 01801
Daniel Robert Jones officer: President, CEO 317 NEW BOSTON STREET, SUITE 210, WOBURN MA 01801
David Pfeffer director 464 IVY AVENUE, HAWORTH NJ 07644
Patrice M. Milos director 317 NEW BOSTON STREET, SUITE 2010, WOBURN MA 01801
Frances P Scally officer: CHIEF FINANCIAL OFFICER 66 MELANIE LANE, SYOSSET NY 11791
John Whitcomb Kennedy officer: CFO, Secretary 166 WINN STREET, WOBURN MA 01801